Analysts Expect DexCom, Inc. (NASDAQ:DXCM) to Post $0.70 Earnings Per Share

Analysts forecast that DexCom, Inc. (NASDAQ:DXCM) will announce earnings per share (EPS) of $0.70 for the current fiscal quarter, Zacks Investment Research reports. Eleven analysts have issued estimates for DexCom’s earnings, with estimates ranging from $0.38 to $0.88. DexCom reported earnings of $0.54 per share in the same quarter last year, which indicates a positive year over year growth rate of 29.6%. The business is expected to issue its next quarterly earnings report on Thursday, February 20th.

According to Zacks, analysts expect that DexCom will report full year earnings of $1.41 per share for the current fiscal year, with EPS estimates ranging from $1.25 to $1.56. For the next financial year, analysts anticipate that the firm will post earnings of $1.75 per share, with EPS estimates ranging from $1.05 to $2.20. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow DexCom.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Wednesday, November 6th. The medical device company reported $0.65 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.45. DexCom had a negative net margin of 12.68% and a positive return on equity of 16.16%. The company had revenue of $396.30 million during the quarter, compared to analyst estimates of $348.99 million. During the same period in the prior year, the firm earned $0.17 earnings per share. The business’s quarterly revenue was up 48.6% on a year-over-year basis.

A number of research firms have commented on DXCM. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $215.00 price objective (up from $190.00) on shares of DexCom in a research note on Thursday, November 7th. Jefferies Financial Group upped their price objective on shares of DexCom from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Guggenheim raised shares of DexCom from a “neutral” rating to a “buy” rating in a research note on Thursday, November 7th. Canaccord Genuity upped their price objective on shares of DexCom from $185.00 to $195.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, Zacks Investment Research raised shares of DexCom from a “hold” rating to a “buy” rating and set a $154.00 price objective for the company in a research note on Friday, October 25th. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $190.67.

In related news, CEO Kevin R. Sayer sold 14,322 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $149.86, for a total value of $2,146,294.92. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Nicholas Augustinos sold 1,208 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $145.49, for a total value of $175,751.92. The disclosure for this sale can be found here. Insiders sold a total of 95,222 shares of company stock worth $14,846,206 in the last quarter. 1.80% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the stock. First Allied Advisory Services Inc. acquired a new position in DexCom in the third quarter worth approximately $271,000. Lyell Wealth Management LP acquired a new position in DexCom in the third quarter worth approximately $2,999,000. BBVA USA Bancshares Inc. acquired a new position in DexCom in the third quarter worth approximately $470,000. Massachusetts Financial Services Co. MA increased its holdings in DexCom by 9.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 200,499 shares of the medical device company’s stock worth $29,922,000 after buying an additional 16,568 shares during the last quarter. Finally, Tower Research Capital LLC TRC acquired a new position in DexCom in the third quarter worth approximately $205,000. Hedge funds and other institutional investors own 96.55% of the company’s stock.

DXCM stock traded up $5.56 during mid-day trading on Friday, reaching $208.37. 1,167,500 shares of the stock traded hands, compared to its average volume of 1,139,446. The company has a current ratio of 5.63, a quick ratio of 5.26 and a debt-to-equity ratio of 1.41. DexCom has a 52-week low of $105.05 and a 52-week high of $208.38. The company has a market cap of $18.87 billion, a P/E ratio of 694.57 and a beta of 0.64. The stock’s fifty day moving average is $161.42 and its 200-day moving average is $148.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: How Investors Can Profit from Options Trading

Get a free copy of the Zacks research report on DexCom (DXCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.